InsidersTradesSigma
Follow the 현대바이오 stock price and the full directors' dealings record of the company, a listed issuer based in South Korea. Shares are listed on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, 현대바이오 has logged 3 reports. Market capitalisation: €727.6bn. The latest transaction was filed on 30 June 2026 (Other). Among the most active insiders: 씨앤팜. The full history is accessible without an account.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Hyundai Bio is a company operating in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative biopharmaceutical solutions.